EDAP Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -9.55% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -39.5% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Edap TMS SA has a consensus price target of $8.50, signalling upside risk potential of 498.59%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 922.13%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Edap TMS SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Edap TMS SA.

Edap TMS SA has a beta of 0.124, which suggesting that the stock is 87.615% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Edap TMS SA's net income of -$2.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Edap TMS SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.76x versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -9.55% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -39.5% beat DBV Technologies SA's return on equity of --.

Edap TMS SA has a consensus price target of $8.50, signalling upside risk potential of 498.59%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 208.06%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

Edap TMS SA has a beta of 0.124, which suggesting that the stock is 87.615% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are larger than DBV Technologies SA quarterly revenues of --. Edap TMS SA's net income of -$2.1M is higher than DBV Technologies SA's net income of -$23M. Notably, Edap TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.76x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -9.55% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -39.5% beat Genfit SA's return on equity of --.

Edap TMS SA has a consensus price target of $8.50, signalling upside risk potential of 498.59%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 210.63%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

Edap TMS SA has a beta of 0.124, which suggesting that the stock is 87.615% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.243%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are larger than Genfit SA quarterly revenues of --. Edap TMS SA's net income of -$2.1M is higher than Genfit SA's net income of --. Notably, Edap TMS SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.76x versus 5.63x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -9.55% compared to Edap TMS SA's net margin of -92.29%. Edap TMS SA's return on equity of -39.5% beat Verona Pharma PLC's return on equity of -88.7%.

Edap TMS SA has a consensus price target of $8.50, signalling upside risk potential of 498.59%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 40.36%. Given that Edap TMS SA has higher upside potential than Verona Pharma PLC, analysts believe Edap TMS SA is more attractive than Verona Pharma PLC.

Edap TMS SA has a beta of 0.124, which suggesting that the stock is 87.615% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.

Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Edap TMS SA quarterly revenues are $21.7M, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Edap TMS SA's net income of -$2.1M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.76x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.